Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
DuPont de Nemours heads into its November 3 earnings report with the Street broadly positive but quietly ratcheting back price targets, a tension worth watching as the stock trades at $133.28.
The clearest signal this week comes from the analyst community. Targets are moving in one direction. Citigroup trimmed its target from $170 to $162 on October 7, while UBS cut from $178 to $172 on October 5. Both firms kept Buy ratings, as did JP Morgan at Overweight. The consensus mean target of $168.75 implies roughly 27% upside from current levels, yet the near-term trajectory of estimate revisions is downward. EPS momentum scores in the 19th to 21st percentile confirm the broader earnings revision picture is weak. The bull case centres on margin expansion in healthcare and water technologies, plus a portfolio transformation that has shed non-core assets and strengthened core franchises. Bears point to elevated debt limiting M&A firepower and sluggish segment recovery. On valuation, DuPont trades at a trailing P/E of 17.1x and EV/EBITDA of 11.3x, both edging higher over the past month as the stock has crept up 1.3%.
The lending market offers no drama at all. Short interest is just 1.1% of the free float, little changed on the week, and availability is extraordinarily loose at nearly 3,000%, meaning roughly 84 million shares remain available to borrow against fewer than 5 million shorted. Cost to borrow is 0.40%, about as low as it gets. Options positioning is equally relaxed. The put/call ratio of 0.267 is almost exactly in line with its 20-day average of 0.263, producing a z-score close to zero. None of the positioning data points to any concentrated bearish bet or defensive hedging ahead of the print.
Institutional ownership is broadly stable. BlackRock held 7.9% as of September 30, adding around 250,000 shares in its latest reported period. State Street also added materially, around 758,000 shares, lifting its stake to 5.1%. No 13D activist is on the register. The insider log is thin: three directors received small equity grants in late August, and a CEO sale of around 261 shares in June was a modest open-market transaction. None of this amounts to a material ownership signal.
One data point worth noting separately is the Wikipedia attention signal. Retail interest in DuPont, measured by English Wikipedia pageviews and ORTEX stock page traffic, is running 1.77 standard deviations above its own 90-day average. This is an attention measure, not a revenue indicator, but the elevated reading is unusual for a large-cap industrial.
The last earnings release, on August 4, produced a 4.3% single-day gain and held most of that over the following week. With November 3 now 27 days away, what to watch is whether the Street's target-trimming pace accelerates or stabilises ahead of the print, and whether the healthcare and water segment commentary supports or challenges the margin-expansion thesis that underpins the consensus Buy.
See the live data behind this article on ORTEX.
Open DD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
